Insulin Therapy and Hypoglycemia in Type 2 Diabetes Mellitus

Insulin

Volumn 2, Issue 3, 2007, Pages 127-133

  Cryer, Philip E ^a   E , Irene ^a   Karl, Michael M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hypoglycemia; insulin; pathophysiology; type 1 diabetes mellitus; type 2 diabetes mellitus

Indexed keywords

INSULIN;

ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN CLEARANCE; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

EID: 34548035395     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(07)80041-8     Document Type: Article

References (34)

1. Cryer P. Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 350 (2004) 2272-2279
2. Nathan D., Buse J., Davidson M., et al., for the Professional Practice Committee, American Diabetes Association, and the European Association for the Study of Diabetes. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972 and
3. Nathan D., Buse J., Davidson M., et al., for the Professional Practice Committee, American Diabetes Association, and the European Association for the Study of Diabetes. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49 (2006) 1711-1721
4. Cryer P., Nathan D., Buse J., Davidson M., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Comment on. Diabetes Care 30 (2007) 190-192 and
5. Cryer P., Nathan D., Buse J., Davidson M., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Comment on. Diabetologia 50 (2007) 222-224
6. Nathan D., and for the Consensus Group. Response to comments on:. In: Nathan D., Buse J., Davidson M., et al. (Eds). Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 30 (2007) 194-196 and
7. Nathan D. for the Consensus Group. Response to comments on:. In: Nathan D., Buse J., Davidson M., et al. (Eds). Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 50 (2007) 231-233 2006
8. Dagogo-Jack S., Craft S., and Cryer P. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest. 91 (1993) 819-828
9. Segel S., Paramore D., and Cryer P. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 51 (2002) 724-733
10. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes 44 (1995) 1249-1258
11. de Heer J., and Hoist J. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes. 56 (2007) 438-443
12. Riddle M., Rosenstock J., Gerich J., and for the Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
13. Cryer P. The prevention and correction of hypoglycemia. In: Jefferson L., and Cherrington A. (Eds). Handbook of Physiology. Section 7, The Endocrine System. Volume II, The Endocrine Pancreas and Regulation of Metabolism (2001), NY: Oxford University Press, New York 1057-1092
14. Towler D., Havlin C., Craft S., and Cryer P. Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 42 (1993) 1791-1798
15. DeRosa M., and Cryer P. Hypoglycemia and the sympathoadrenal system: Neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab 287 (2004) E32-E41
16. Raju B., and Cryer P. Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: Documentation of the intraislet insulin hypothesis in humans. Diabetes 54 (2005) 757-764
17. Cryer P. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes 54 (2005) 3592-3601
18. Cryer P. Mechanisms of sympathoadrenal failure and hypoglycemia in diabetes. J Clin Invest 116 (2006) 1470-1473
19. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 128 (1998) 165-175
20. Hepburn D., MacLeod K., Pell A., et al. Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med 10 (1993) 231-237
21. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46 (1997) 271-286
22. Wright A., Cull C., Macleod K., Holman R., and for the UKPDS Group. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS 73. J Diabetes Complications 20 (2006) 395-401
23. Henderson J., Allen K., Deary I., and Frier B. Hypoglycaemia in insulin-treated type 2 diabetes: Frequency, symptoms and impaired awareness. Diabet Med 20 (2003) 1016-1021
24. Akram K., Pedersen-Bjergaard U., Carstensen B., et al. Frequency and risk factors for severe hypoglycaemia in insulin-treated type 2 diabetes: A cross-sectional survey. Diabet Med 23 (2006) 750-756
25. Donnelly L., Morris A., Frier B., et al., for the DARTS/MEMO Collaboration. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: A population-based study. Diabet Med 22 (2005) 749-755
26. Holstein A., Plaschke A., and Egberts E. Clinical characterization of severe hypoglycaemia-a prospective population-based study. Exp Clin Endocrinol Diabetes 111 (2003) 364-369
27. Leese G., Wang J., Broomhall J., et al., for the DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A population based study of health service resource use. Diabetes Care 26 (2003) 1176-1180
28. Cryer P., Davis S., and Shamoon H. Hypoglycemia in diabetes. Diabetes Care 26 (2003) 1902-1912
29. The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 90 (1991) 450-459
30. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
31. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). [published correction appears in Lancet. 1999;354:602]. Lancet 352 (1998) 837-853
32. Hirsch l. Insulin analogues. N EnglJ Med 352 (2005) 174-183
33. Gangji A., Cukierman T., Gerstein H., et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: A comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30 (2007) 389-394
34. Raju B., Arbelaez A., Breckenridge S., and Cryer P. Nocturnal hypoglycemia in type 1 diabetes: An assessment of preventive bedtime treatments. J Clin Endocrinol Metab 91 (2006) 2087-2092